Objectives: To investigate the relationship between insomnia (INS) combined with chronic musculoskeletal pain (MSP) in postmenopausal women and its characteristics regarding MSP, menopausal and mood symptoms, sleep and quality of life (QOL). Methods: A cross-sectional control study in 4 groups of postmenopausal women: control (n = 15), MSP (n = 15), INS (n = 15) and INS + MSP (n = 17). Sixty-two participants completed questionnaires and had blood collected, and 43 underwent polysomnography. Results: INS was associated with increased anxiety (P = 0.04) and sleep fragmentation (P = 0.02); worse MSP severity (P = 0.00), MSP interference with daily function (P = 0.00), higher pain intensity at midday (P = 0.02) and menopausal symptoms (P = 0.00); and reduced QOL (P = 0.00). MSP was associated with increased anxiety (P = 0.02) and menopausal symptoms (P = 0.00), and reduced QOL (P = 0.05). In the whole sample, depression symptoms were higher but no statistical differences were found between groups (P = 0.47). Worse QOL was associated with both higher depressive symptoms (P = 0.01) and worse pain interference (P = 0.02). 
Introduction
Menopause is the permanent cessation of the menstrual cycles following the loss of ovarian reproductive function and is a natural physiological process related to aging. 1 The postmenopausal period is clinically and retrospectively diagnosed with the following amenorrhea for more than 12
months.
There is evidence of a worsening quality of life (QOL) after menopause, especially in relation to the presence of climacteric symptoms, their frequency and intensity. INS seems to influence the onset and level of MSP in different populations, 4 although most studies focus on both sexes and different age ranges, rather than specifically in J MM postmenopausal women. The co-occurrence of poor sleep quality, pain, and mood symptoms, such as anxiety and depression is evidenced in the literature and presented as a cluster of symptoms in women. 5 However, there is no evidence in the literature about the association between chronic MSP complaints and INS in postmenopausal women and its characteristics regarding MSP, menopausal and mood symptoms, sleep and and QOL. We also aimed to examine the predictor factors for menopausal symptoms and QOL.
Materials and Methods 
Ethical aspects

Recruitment criteria
A total of 355 women were assessed for eligibility to take part in the study, with 62 being selected after the evaluation of the inclusion and exclusion criteria (Fig. 1) . The inclusion criteria consisted of being women aged 50 to 65 years; and late, which covers the subsequent period. 8 
Questionnaires
Brief Pain Inventory -MSP severity and MSP interference with daily function.
This questionnaire was used to evaluate the severity and interference of MSP. 9 The answers are distributed on a numerical scale from 0-10, with 0 representing "does not interfere" and 10 representing "interferes completely" .
Pain visual analog scale (VAS) -pain intensity
Participants completed 3 times a day over 10 days a pain diary, composed of an average pain rating on a VAS (0 "no pain" , 10 "worst pain imaginable" ). 10 VAS scores were averaged across days for each period to assess the intensity of chronic MSP during the day.
Menopausal symptomatology
The Menopause Rating Scale accessed menopausal symptoms in 3 domains: somatic, psychological and urogenital. Sidak post hoc analysis when necessary. All analyses were conducted using SPSS version 18 software (SPSS Inc., Chicago, IL, USA). Statistical significance was set at P ≤ 0.05.
Results
From a total of 75 women who entered the protocol, 62
were eligible and were allocated into 4 groups: control, MSP,
INS, and INS + MSP (Fig. 1). The sample was homogeneous
as demonstrated in Table 1 , except for age, with the INS group being older than all other groups (F = 3.88, df = 1, P = 0.05), and the presence of hypertension in the INS group was significantly higher compared to the other groups (χ 2 = 9.1; df = 1; P = 0.03).
INS and MSP were individually and independently associated with higher MSP severity (F = 10.31, df = 1, P = 0.002; F = 15.27, df = 1, P = 0.000; respectively, Table 2 ). 2). In relation to the Menopause Rating Scale domains, the somatic (F = 10.52, df = 3, P = 0.000), and the psychologic (F = 9.98, df = 3, P = 0.000) domains presented the same pattern (Fig. 3) . We found no significant statistical difference among groups in the urogenital domain (F = 1.19, df = 3, P = 0.32).
In relation to mood symptoms, INS alone (F = 9.20, df = 1, P = 0.04) and MSP alone increase anxiety symptoms (F = 5.33, df = 1, P = 0.02). Regarding depression symptoms, no statistical differences were observed among the groups (F = 0.53, df = 1, P = 0.47; Table 3 ).
No significant differences were observed among the groups regarding vasomotor symptoms (F = 0.67, df = 1, P = 0.42; Table 3 ). Table 4 ). Table 3 ).
As shown in Table 5 , the generalized linear model showed increased symptoms of anxiety and depression, as well as INS severity, were positively associated with higher menopausal symptoms. Each 1-unit increase in anxiety symptoms score was associated with a 50% addition in the menopausal symptoms score. Each 1-unit increase in depressive symptoms score and INS severity score were associated with a 2.1-fold and 3.6-fold increase of menopausal symptoms score, respectively.
Regarding the predictor factors of QOL in the whole sample of women included in the current study, the results showed that each 1-unit increase of depressive symptoms score was associated with a 10% decrease in QOL. Additionally, each 1-unit increase in pain interference score was associated with a 30% decrease in QOL (Table 6 ).
Discussion
This is the first study, to the best of our knowledge, to show the characteristics of INS + MSP combined on in- Chronic MSP conditions have been linked to disturbed sleep 10, 11 and short sleep duration (< 360 min). 4 INS alone was associated with increased pain intensity at midday. A study by Tang and colleagues, 20 in the general population, showed that sleep helped to reduce pain intensity. A possible hypothesis for this is that sleep deprivation increases plasma levels of cortisol which is responsible for increased pain sensitivity. Cortisol concentrations start to decline from midday and reach their lowest concentrations in the late evening and during the early part of the sleep period. 21 In addition, the presence of restorative sleep seems to reduce chronic generalized pain 22 and in our sample, this Another hypothesis is related to the midday body temperature decline. The body temperature is a biologic rhythm closely associated with the circadian rhythm of sleepiness. 23 The thermoregulatory mechanism that lowers body temperature and the decline in cortisol concentrations can promote sleep. We speculate that both could have influenced the increased perception of MSP at midday, so the relief of pain generated by sleep was evident only until the first half of the day. Moreover, our sample did not present daytime sleepiness. There are some limitations in this study that should be considered. First, this was a cross-sectional design, which does not allow the establishment of causality between factors. Second, the MSP was assessed through self-reported data while combined subjective and objective data may be more suitable for research (e.g., Quantitative Sensory Testing). Third, the information about comorbidities was based on the participants' self-reports. Lastly, there was no night of adaptation for the PSG exam, which may decrease overall the sleep quality of the participants from all groups.
The present results demonstrate that INS + MSP combined was related to higher menopausal and anxiety symptoms, more sleep fragmentation, more complaints of MSP severity and interference, more pain sites and worse QOL. J MM
